Annual CFO
-$58.79 M
+$88.12 M+59.98%
31 December 2023
Summary:
Heron Therapeutics annual cash flow from operations is currently -$58.79 million, with the most recent change of +$88.12 million (+59.98%) on 31 December 2023. During the last 3 years, it has risen by +$126.03 million (+68.19%). HRTX annual CFO is now -740.33% below its all-time high of $9.18 million, reached on 31 December 2006.HRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$3.37 M
+$7.97 M+173.22%
30 September 2024
Summary:
Heron Therapeutics quarterly cash flow from operations is currently $3.37 million, with the most recent change of +$7.97 million (+173.22%) on 30 September 2024. Over the past year, it has increased by +$12.55 million (+136.73%). HRTX quarterly CFO is now -83.49% below its all-time high of $20.42 million, reached on 31 March 2006.HRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$8.29 M
+$12.55 M+60.21%
30 September 2024
Summary:
Heron Therapeutics TTM cash flow from operations is currently -$8.29 million, with the most recent change of +$12.55 million (+60.21%) on 30 September 2024. Over the past year, it has increased by +$90.48 million (+91.60%). HRTX TTM CFO is now -156.54% below its all-time high of $14.67 million, reached on 31 March 2006.HRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +60.0% | +136.7% | +91.6% |
| 3 y3 years | +68.2% | +106.3% | +96.1% |
| 5 y5 years | +69.3% | +113.2% | +93.7% |
HRTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +71.1% | at high | +106.3% | at high | +96.1% |
| 5 y | 5 years | at high | +71.1% | at high | +105.3% | at high | +96.1% |
| alltime | all time | -740.3% | +71.1% | -83.5% | +105.3% | -156.5% | +96.1% |
Heron Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.37 M(-173.2%) | -$8.29 M(-60.2%) |
| June 2024 | - | -$4.60 M(-51.6%) | -$20.84 M(-52.0%) |
| Mar 2024 | - | -$9.52 M(-487.6%) | -$43.41 M(-26.2%) |
| Dec 2023 | -$58.79 M(-60.0%) | $2.46 M(-126.7%) | -$58.79 M(-40.5%) |
| Sept 2023 | - | -$9.18 M(-66.2%) | -$98.78 M(-22.0%) |
| June 2023 | - | -$27.16 M(+9.1%) | -$126.67 M(-0.9%) |
| Mar 2023 | - | -$24.90 M(-33.7%) | -$127.87 M(-13.0%) |
| Dec 2022 | -$146.91 M(-27.8%) | -$37.53 M(+1.3%) | -$146.91 M(-5.0%) |
| Sept 2022 | - | -$37.07 M(+30.6%) | -$154.64 M(-9.4%) |
| June 2022 | - | -$28.37 M(-35.4%) | -$170.74 M(-16.9%) |
| Mar 2022 | - | -$43.94 M(-2.9%) | -$205.35 M(+1.0%) |
| Dec 2021 | -$203.35 M(+10.0%) | -$45.26 M(-14.9%) | -$203.35 M(-3.5%) |
| Sept 2021 | - | -$53.17 M(-15.6%) | -$210.65 M(+5.6%) |
| June 2021 | - | -$62.99 M(+50.2%) | -$199.54 M(+2.9%) |
| Mar 2021 | - | -$41.94 M(-20.2%) | -$193.82 M(+4.9%) |
| Dec 2020 | -$184.82 M(+48.4%) | -$52.55 M(+25.0%) | -$184.82 M(+16.1%) |
| Sept 2020 | - | -$42.05 M(-26.6%) | -$159.24 M(+11.6%) |
| June 2020 | - | -$57.28 M(+73.9%) | -$142.66 M(+31.5%) |
| Mar 2020 | - | -$32.94 M(+22.1%) | -$108.49 M(-12.9%) |
| Dec 2019 | -$124.58 M(-35.0%) | -$26.98 M(+5.9%) | -$124.58 M(-5.0%) |
| Sept 2019 | - | -$25.47 M(+10.2%) | -$131.09 M(-7.4%) |
| June 2019 | - | -$23.11 M(-52.9%) | -$141.50 M(-21.0%) |
| Mar 2019 | - | -$49.02 M(+46.4%) | -$179.12 M(-6.6%) |
| Dec 2018 | -$191.81 M(+12.6%) | -$33.49 M(-6.7%) | -$191.81 M(-6.6%) |
| Sept 2018 | - | -$35.88 M(-40.9%) | -$205.47 M(-2.2%) |
| June 2018 | - | -$60.73 M(-1.6%) | -$210.13 M(+15.8%) |
| Mar 2018 | - | -$61.71 M(+30.9%) | -$181.43 M(+6.5%) |
| Dec 2017 | -$170.30 M(+27.0%) | -$47.15 M(+16.3%) | -$170.30 M(+5.3%) |
| Sept 2017 | - | -$40.54 M(+26.6%) | -$161.67 M(+2.8%) |
| June 2017 | - | -$32.03 M(-36.7%) | -$157.25 M(+3.2%) |
| Mar 2017 | - | -$50.58 M(+31.3%) | -$152.33 M(+13.6%) |
| Dec 2016 | -$134.10 M(+70.8%) | -$38.52 M(+6.7%) | -$134.10 M(+12.9%) |
| Sept 2016 | - | -$36.12 M(+33.2%) | -$118.73 M(+15.8%) |
| June 2016 | - | -$27.11 M(-16.2%) | -$102.50 M(+12.4%) |
| Mar 2016 | - | -$32.35 M(+39.7%) | -$91.21 M(+16.2%) |
| Dec 2015 | -$78.53 M(+30.3%) | -$23.15 M(+16.4%) | -$78.53 M(+15.1%) |
| Sept 2015 | - | -$19.89 M(+25.7%) | -$68.23 M(+1.0%) |
| June 2015 | - | -$15.82 M(-19.6%) | -$67.58 M(+5.2%) |
| Mar 2015 | - | -$19.67 M(+53.0%) | -$64.24 M(+6.6%) |
| Dec 2014 | -$60.28 M(+47.9%) | -$12.86 M(-33.2%) | -$60.28 M(+5.7%) |
| Sept 2014 | - | -$19.24 M(+54.2%) | -$57.05 M(+13.7%) |
| June 2014 | - | -$12.48 M(-20.6%) | -$50.17 M(+3.4%) |
| Mar 2014 | - | -$15.71 M(+63.2%) | -$48.52 M(+19.0%) |
| Dec 2013 | -$40.76 M(+139.7%) | -$9.63 M(-22.1%) | -$40.76 M(+9.4%) |
| Sept 2013 | - | -$12.35 M(+14.2%) | -$37.26 M(+34.5%) |
| June 2013 | - | -$10.82 M(+35.9%) | -$27.71 M(+32.8%) |
| Mar 2013 | - | -$7.96 M(+30.0%) | -$20.86 M(+22.7%) |
| Dec 2012 | -$17.01 M(+120.3%) | -$6.13 M(+118.3%) | -$17.01 M(+27.3%) |
| Sept 2012 | - | -$2.81 M(-29.3%) | -$13.36 M(+1.1%) |
| June 2012 | - | -$3.97 M(-3.3%) | -$13.21 M(+22.3%) |
| Mar 2012 | - | -$4.11 M(+65.9%) | -$10.80 M(+39.9%) |
| Dec 2011 | -$7.72 M(+40.8%) | -$2.48 M(-6.9%) | -$7.72 M(+25.2%) |
| Sept 2011 | - | -$2.66 M(+69.9%) | -$6.17 M(0.0%) |
| June 2011 | - | -$1.56 M(+52.7%) | -$6.17 M(-4.3%) |
| Mar 2011 | - | -$1.02 M(+11.3%) | -$6.45 M(+17.6%) |
| Dec 2010 | -$5.48 M(-50.2%) | -$920.00 K(-65.4%) | -$5.48 M(-16.5%) |
| Sept 2010 | - | -$2.66 M(+44.1%) | -$6.56 M(+7.4%) |
| June 2010 | - | -$1.84 M(+2923.0%) | -$6.11 M(-23.5%) |
| Mar 2010 | - | -$61.00 K(-97.0%) | -$7.99 M(-27.4%) |
| Dec 2009 | -$11.00 M(-54.7%) | -$2.00 M(-9.3%) | -$11.00 M(-26.9%) |
| Sept 2009 | - | -$2.21 M(-40.7%) | -$15.04 M(-15.5%) |
| June 2009 | - | -$3.72 M(+21.2%) | -$17.80 M(-12.6%) |
| Mar 2009 | - | -$3.07 M(-49.1%) | -$20.36 M(-16.1%) |
| Dec 2008 | -$24.27 M(+40.5%) | -$6.04 M(+21.5%) | -$24.27 M(+7.4%) |
| Sept 2008 | - | -$4.97 M(-20.9%) | -$22.59 M(-1.2%) |
| June 2008 | - | -$6.28 M(-10.1%) | -$22.86 M(+26.4%) |
| Mar 2008 | - | -$6.99 M(+60.3%) | -$18.10 M(+4.7%) |
| Dec 2007 | -$17.28 M | -$4.36 M(-16.8%) | -$17.28 M(+7.8%) |
| Sept 2007 | - | -$5.24 M(+246.3%) | -$16.04 M(+11.3%) |
| June 2007 | - | -$1.51 M(-75.5%) | -$14.41 M(-17.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$6.17 M(+98.1%) | -$17.41 M(-289.6%) |
| Dec 2006 | $9.18 M(-222.0%) | -$3.11 M(-13.9%) | $9.18 M(-9.3%) |
| Sept 2006 | - | -$3.62 M(-19.7%) | $10.13 M(-17.0%) |
| June 2006 | - | -$4.50 M(-122.1%) | $12.20 M(-16.8%) |
| Mar 2006 | - | $20.42 M(-1041.4%) | $14.67 M(-294.9%) |
| Dec 2005 | -$7.53 M(+1.3%) | -$2.17 M(+40.8%) | -$7.53 M(+11.9%) |
| Sept 2005 | - | -$1.54 M(-24.5%) | -$6.72 M(+2.3%) |
| June 2005 | - | -$2.04 M(+14.7%) | -$6.57 M(-10.5%) |
| Mar 2005 | - | -$1.78 M(+30.2%) | -$7.34 M(-1.2%) |
| Dec 2004 | -$7.43 M(+17.3%) | -$1.37 M(-1.4%) | -$7.43 M(-0.6%) |
| Sept 2004 | - | -$1.39 M(-50.7%) | -$7.47 M(+7.5%) |
| June 2004 | - | -$2.81 M(+50.7%) | -$6.95 M(+8.5%) |
| Mar 2004 | - | -$1.86 M(+32.4%) | -$6.41 M(+1.2%) |
| Dec 2003 | -$6.33 M(+23.3%) | -$1.41 M(+63.1%) | -$6.33 M(+3.4%) |
| Sept 2003 | - | -$864.00 K(-61.9%) | -$6.12 M(-5.3%) |
| June 2003 | - | -$2.27 M(+26.6%) | -$6.46 M(+15.4%) |
| Mar 2003 | - | -$1.79 M(+49.4%) | -$5.60 M(+9.1%) |
| Dec 2002 | -$5.13 M(-21.0%) | -$1.20 M(-0.6%) | -$5.13 M(-16.3%) |
| Sept 2002 | - | -$1.21 M(-14.3%) | -$6.14 M(-10.0%) |
| June 2002 | - | -$1.41 M(+6.4%) | -$6.82 M(+7.2%) |
| Mar 2002 | - | -$1.32 M(-39.9%) | -$6.36 M(-2.2%) |
| Dec 2001 | -$6.50 M(+108.4%) | -$2.20 M(+16.7%) | -$6.50 M(+11.6%) |
| Sept 2001 | - | -$1.89 M(+99.3%) | -$5.82 M(+20.5%) |
| June 2001 | - | -$946.50 K(-35.3%) | -$4.83 M(+7.0%) |
| Mar 2001 | - | -$1.46 M(-4.3%) | -$4.51 M(+44.9%) |
| Dec 2000 | -$3.12 M(+289.5%) | -$1.53 M(+70.8%) | -$3.12 M(+261.2%) |
| Sept 2000 | - | -$894.50 K(+41.8%) | -$862.70 K(<-9900.0%) |
| June 2000 | - | -$630.70 K(+894.8%) | $5900.00(-100.8%) |
| Mar 2000 | - | -$63.40 K(-108.7%) | -$763.40 K(-4.6%) |
| Dec 1999 | -$800.00 K(-70.4%) | $725.90 K(-2902.7%) | -$800.00 K(-56.2%) |
| Sept 1999 | - | -$25.90 K(-98.2%) | -$1.83 M(+1.4%) |
| June 1999 | - | -$1.40 M(+1300.0%) | -$1.80 M(+200.0%) |
| Mar 1999 | - | -$100.00 K(-66.7%) | -$600.00 K(-77.8%) |
| Dec 1998 | -$2.70 M(<-9900.0%) | -$300.00 K(<-9900.0%) | -$2.70 M(+80.0%) |
| Sept 1998 | - | $0.00(-100.0%) | -$1.50 M(+7.1%) |
| June 1998 | - | -$200.00 K(-90.9%) | -$1.40 M(-44.0%) |
| Mar 1998 | - | -$2.20 M(-344.4%) | -$2.50 M(<-9900.0%) |
| Dec 1997 | $0.00(-100.0%) | $900.00 K(+800.0%) | $0.00(-100.0%) |
| Sept 1997 | - | $100.00 K(-107.7%) | -$1.30 M(-40.9%) |
| June 1997 | - | -$1.30 M(-533.3%) | -$2.20 M(+4.8%) |
| Mar 1997 | - | $300.00 K(-175.0%) | -$2.10 M(-65.6%) |
| Dec 1996 | -$6.10 M(-28.2%) | -$400.00 K(-50.0%) | -$6.10 M(-26.5%) |
| Sept 1996 | - | -$800.00 K(-33.3%) | -$8.30 M(-18.6%) |
| June 1996 | - | -$1.20 M(-67.6%) | -$10.20 M(-13.6%) |
| Mar 1996 | - | -$3.70 M(+42.3%) | -$11.80 M(+38.8%) |
| Dec 1995 | -$8.50 M(-1.2%) | -$2.60 M(-3.7%) | -$8.50 M(-4.5%) |
| Sept 1995 | - | -$2.70 M(-3.6%) | -$8.90 M(+2.3%) |
| June 1995 | - | -$2.80 M(+600.0%) | -$8.70 M(+2.4%) |
| Mar 1995 | - | -$400.00 K(-86.7%) | -$8.50 M(-1.2%) |
| Dec 1994 | -$8.60 M(-26.5%) | -$3.00 M(+20.0%) | -$8.60 M(+6.2%) |
| Sept 1994 | - | -$2.50 M(-3.8%) | -$8.10 M(0.0%) |
| June 1994 | - | -$2.60 M(+420.0%) | -$8.10 M(-17.3%) |
| Mar 1994 | - | -$500.00 K(-80.0%) | -$9.80 M(-16.2%) |
| Dec 1993 | -$11.70 M(+200.0%) | -$2.50 M(0.0%) | -$11.70 M(+0.9%) |
| Sept 1993 | - | -$2.50 M(-41.9%) | -$11.60 M(+46.8%) |
| June 1993 | - | -$4.30 M(+79.2%) | -$7.90 M(+92.7%) |
| Mar 1993 | - | -$2.40 M(0.0%) | -$4.10 M(+5.1%) |
| Dec 1992 | -$3.90 M(+2.6%) | -$2.40 M(-300.0%) | -$3.90 M(+30.0%) |
| Sept 1992 | - | $1.20 M(-340.0%) | -$3.00 M(-45.5%) |
| June 1992 | - | -$500.00 K(-77.3%) | -$5.50 M(+5.8%) |
| Mar 1992 | - | -$2.20 M(+46.7%) | -$5.20 M(+36.8%) |
| Dec 1991 | -$3.80 M(+11.8%) | -$1.50 M(+15.4%) | -$3.80 M(+31.0%) |
| Sept 1991 | - | -$1.30 M(+550.0%) | -$2.90 M(+11.5%) |
| June 1991 | - | -$200.00 K(-75.0%) | -$2.60 M(-29.7%) |
| Mar 1991 | - | -$800.00 K(+33.3%) | -$3.70 M(+8.8%) |
| Dec 1990 | -$3.40 M(-10.5%) | -$600.00 K(-40.0%) | -$3.40 M(+21.4%) |
| Sept 1990 | - | -$1.00 M(-23.1%) | -$2.80 M(+55.6%) |
| June 1990 | - | -$1.30 M(+160.0%) | -$1.80 M(+260.0%) |
| Mar 1990 | - | -$500.00 K | -$500.00 K |
| Dec 1989 | -$3.80 M | - | - |
FAQ
- What is Heron Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Heron Therapeutics?
- What is Heron Therapeutics annual CFO year-on-year change?
- What is Heron Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Heron Therapeutics?
- What is Heron Therapeutics quarterly CFO year-on-year change?
- What is Heron Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Heron Therapeutics?
- What is Heron Therapeutics TTM CFO year-on-year change?
What is Heron Therapeutics annual cash flow from operations?
The current annual CFO of HRTX is -$58.79 M
What is the all time high annual CFO for Heron Therapeutics?
Heron Therapeutics all-time high annual cash flow from operations is $9.18 M
What is Heron Therapeutics annual CFO year-on-year change?
Over the past year, HRTX annual cash flow from operations has changed by +$88.12 M (+59.98%)
What is Heron Therapeutics quarterly cash flow from operations?
The current quarterly CFO of HRTX is $3.37 M
What is the all time high quarterly CFO for Heron Therapeutics?
Heron Therapeutics all-time high quarterly cash flow from operations is $20.42 M
What is Heron Therapeutics quarterly CFO year-on-year change?
Over the past year, HRTX quarterly cash flow from operations has changed by +$12.55 M (+136.73%)
What is Heron Therapeutics TTM cash flow from operations?
The current TTM CFO of HRTX is -$8.29 M
What is the all time high TTM CFO for Heron Therapeutics?
Heron Therapeutics all-time high TTM cash flow from operations is $14.67 M
What is Heron Therapeutics TTM CFO year-on-year change?
Over the past year, HRTX TTM cash flow from operations has changed by +$90.48 M (+91.60%)